Reuters logo
BRIEF-FDA grants priority review to Gilotrif
October 10, 2017 / 1:20 PM / 2 months ago

BRIEF-FDA grants priority review to Gilotrif

Oct 10 (Reuters) - Boehringer Ingelheim

* FDA grants priority review to gilotrif® for uncommon egfr mutations in advanced nsclc

* ‍Boehringer Ingelheim says that supplemental New Drug Application for Gilotrif (afatinib) has been accepted for filing and granted priority review by U.S. FDA Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below